title: Diffuse large cell lymphoma. Prognostic factors with treatment.
abstract: Five successive chemotherapy protocols for stages II, III and IV diffuse large cell lymphoma (DLCL) have resulted in identical overall survivals. Between 35% to 45% of patients survived. In a multivariate analysis employing the Weibull model 3 factors were associated with shortened survival: bulky mediastinal and/or retroperitoneal disease, elevated serum LDH and advanced age. In young patients with bulky mediastinal and/or retroperitoneal disease and high serum LDH, autologous bone marrow transplantation following high dose chemotherapy and radiation therapy (RT) as part of the initial treatment have produced more promising results. In a randomized trial, a significantly longer disease-free survival was found for patients with stages I or IE diffuse lymphomas with RT followed by adjuvant chemotherapy than with RT alone.
authors.affiliation: Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
authors.forename: D J
authors.initials: DJ
authors.lastname: Straus
authors.forename: G
authors.initials: G
authors.lastname: Wong
authors.forename: J
authors.initials: J
authors.lastname: Yahalom
authors.forename: G
authors.initials: G
authors.lastname: Varsos
authors.forename: S
authors.initials: S
authors.lastname: Gulati
authors.forename: B
authors.initials: B
authors.lastname: Clarkson
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D016019:Survival Analysis